Article

Depression Higher in Poor Rheumatoid Arthritis Patients

Low socioeconomic status (SES) is associated with higher risk of depressive symptoms in patients with rheumatoid arthritis.

Low socioeconomic status (SES) is associated with higher risk of depressive symptoms in patients with rheumatoid arthritis (RA), according to a study published in Wiley-Blackwell Arthritis Care & Research.

Statistically significant differences in race, public versus tertiary-care hospital, disability and medications were found between depressed and non-depressed patients.

Roughly 1.3 million Americans are affected by RA—a chronic autoimmune disease that can cause functional limitations and may lead to physical disability in many patients. Prior studies have shown that depression is common, occurring in 13 to 42% of RA patients and is associated with worse outcomes, including greater risk of heart attack, suicide, and death. In the US, socioeconomic position as measured by race, gender, age, income, education, and health access has significant impact on overall health.

Mary Margaretten, MD, from the Arthritis Research Group at the University of California, San Francisco (UCSF) and lead study author, said, in a press release, "We assessed the extent to which low SES influences the relationship between disability and depression in order to better identify those patients at higher risk for depression."

Researchers used data obtained from the UCSF RA cohort,in which participants were enrolled from an urban county, public hospital that serves the poor and a referral, tertiary-care medical center. The data included 824 visits for 466 patients, 223 from the public hospital and 243 from the tertiary-care clinic.

Analysis showed that 37% of participants had moderate to severe depression, scoring 10 or higher on the Patient Health Questionnaire (PHQ-9). The mean Health Assessment Questionnaire (HAQ) score was 1.2 and the disease activity score (DAS28) was 4, indicating fairly high levels of functional impairment and disease activity, respectively. Researchers also found significant differences between depressed and non-depressed patients related to race, public versus university hospital, functional limitation and disease modifying anti-rheumatic drug (DMARD) treatment. Differences in depression severity were not impacted by gender, age, disease duration, steroid use and dose, or biologic therapy.

Furthermore, the team found that county hospital patients also had significantly higher depression scores (PHQ-9 of 7.3) than patients at the university medical center (PHQ-9 of 5.7). An interaction existed between socioeconomic status and disability such that the association of functional limitation with depression scores was stronger for patients at the public hospital clinic compared to those at the tertiary-care clinic.

Margaretten said, "For the same level of disability, patients with low SES may be more likely to experience depression. Detection and documentation of the differing effects of disability on depression between patients of different socioeconomic status can help rheumatologists improve health outcomes by initiating appropriate and timely treatment for depression."

The study is titled, "Socioeconomic Determinants of Disability and Depression in Patients with Rheumatoid Arthritis."

Source: Wiley-Blackwell--Are the findings consistent with what you have come across? Leave a comment.

Related Videos
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
Shreena K. Gandhi, MBBS: Recognizing Fibromyalgia as a Continuous Variable, Trait Diagnosis
Reducing Treatment Burden of Pegloticase for Uncontrolled Gout, with Orrin Troum, MD
Exploring CAR T-cell Therapy for Rheumatic/Autoimmune Diseases With Georg Schett, MD
John Stone, MD, MPH: Inebilizumab Efficacious for IgG4-Related Disease in MITIGATE Study
Parent Stress Reduces Over Time When Weaning Child Off Tube Feeding with Hide Okuno, MS
© 2024 MJH Life Sciences

All rights reserved.